Welcome to Paid Research Studies




  • Condition:   Chronic Kidney Diseases
    Interventions:   Drug: Pioglitazone;   Other: Placebo
    Sponsor:   The University of Texas at Arlington
    Recruiting

  • Conditions:   Myositis;   Inclusion Body Myositis;   Muscular Diseases;   Musculoskeletal Disease;   Neuromuscular Diseases;   Nervous System Diseases
    Intervention:   Drug: Pioglitazone
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Multiple Sclerosis
    Interventions:   Drug: Pioglitazone;   Drug: Montelukast;   Drug: Losartan;   Drug: Hydroxychloroquine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Alcoholism
    Intervention:   Drug: Pioglitazone
    Sponsors:   Emory University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting

  • Conditions:   Diabetes Mellitus, Type 2;   Impaired Glucose Tolerance (IGT);   Impaired Fasting Glucose (IFG)
    Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Pioglitazone;   Drug: Metformin
    Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   AstraZeneca;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Obese;   Metabolic Syndrome
    Interventions:   Drug: Mirabegron;   Drug: Pioglitazone;   Drug: Mirabegron and Pioglitazone
    Sponsors:   Philip Kern;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Oral Cavity Neoplasm;   Oropharyngeal Neoplasm;   Stage 0 Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet;   Other: Pharmacological Study;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Pioglitazone;   Drug: Tyrosine Kinase Inhibitor (TKI)
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Rheumatoid Arthritis;   Insulin Resistance
    Interventions:   Drug: Pioglitazone;   Drug: Placebo
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Condition:   Systemic Lupus Erthematosus
    Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
    Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting

  • Condition:   Diabetes
    Interventions:   Drug: metformin\pioglitazone\exenatide;   Drug: metformin, glyburide and glargine
    Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   Amylin Pharmaceuticals, LLC.;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Uric Acid Kidney Stone Disease
    Interventions:   Drug: Pioglitazone;   Drug: Placebo
    Sponsors:   University of Texas Southwestern Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Takeda Pharmaceuticals North America, Inc.
    Recruiting